Research record
Overview
Compound name: Semaglutide
Compound classification: Synthetic peptide; glucagon-like peptide-1 (GLP-1) receptor agonist
Brief factual description:
Semaglutide is a long-acting synthetic analog of human GLP-1 engineered to resist enzymatic degradation and extend plasma half-life. It enhances glucose-dependent insulin secretion, suppresses appetite, and slows gastric emptying, making it effective in the management of type 2 diabetes and obesity.
Mechanism of Action
Primary biological targets: GLP-1 receptor (GLP-1R)
Affected systems: Endocrine, metabolic, gastrointestinal, central nervous system
Receptor selectivity:
High specificity for GLP-1 receptor
Downstream signaling effects:
Glucose-dependent insulin secretion
Suppression of glucagon release
Delayed gastric emptying
Central appetite suppression via hypothalamic pathways




